Are These ASX Pharma Stocks Worth Watching in September 2026?

Sonal Goyal

14 September 2026 05:50 PM AEST

Are These ASX Pharma Stocks Worth Watching in September 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Botanix Pharmaceuticals Limited (ASX:BOT), Clinuvel Pharmaceuticals Limited (ASX:CUV) and Mayne Pharma Group Limited (ASX:MYX) operate across different areas of specialty medicine. Botanix is commercialising a dermatology product in the United States, Clinuvel generates Revenue from an established rare-disease medicine while funding further clinical development, and Mayne Pharma operates across women’s health, dermatology and specialty pharmaceuticals.

Their FY2026 financial profiles differ substantially. Botanix remains in a cash-intensive commercialisation phase, Clinuvel continues to generate sizeable profit and cash, while Mayne Pharma operates from a much larger revenue base but with pressure on underlying earnings.

Specialty Pharma Outlook

Specialty pharmaceutical companies are influenced by prescription volumes, payer coverage, product mix and distribution economics. Even where a medicine is approved, the level of net revenue retained after rebates and other commercial deductions can materially affect profitability.

For smaller ASX healthcare companies, cash generation remains an important measure. Companies with established products and positive Earnings can fund pipeline development internally, while earlier commercial-stage businesses may still depend on external Capital as sales scale.

Botanix Pharmaceuticals Limited (ASX:BOT)

Company Profile

Botanix Pharmaceuticals is a dermatology-focused company commercialising Sofdra in the United States for primary axillary hyperhidrosis.

The company has built a direct-to-patient distribution model intended to improve prescription fulfilment and support reimbursement management.

FY2026 Financial Performance

Botanix reported net product sales receipts of AUD 44.8 million for FY2026.

During the June quarter, net revenue reached AUD 10.1 million as prescription volumes increased and the gross-to-net ratio improved.

Full-year operating cash outflow was AUD 64.3 million.

Cash at 30 June 2026 stood at AUD 36.6 million following Equity funding completed during the year.

The company also implemented cost reductions across its commercial operations as it works toward narrowing cash burn.

Outlook and Risks

Botanix remains focused on prescription growth and improving the proportion of gross sales converted into net revenue.

The main Financial Risk is the gap between current cash resources and the level of operating expenditure required to support the US launch.

Further improvement in commercial Economics will therefore be important if Botanix is to reduce reliance on additional capital.

Clinuvel Pharmaceuticals Limited (ASX:CUV)

Company Profile

Clinuvel Pharmaceuticals develops and commercialises treatments for rare and specialised disorders.

Its principal commercial product is SCENESSE, which is approved for erythropoietic protoporphyria across multiple markets. The company is also investing in additional indications, including vitiligo.

FY2026 Financial Performance

Clinuvel reported FY2026 revenue plus interest and other income reached AUD 101.2 million.

Net profit after tax was AUD 33.9 million.

Cash reserves stood at AUD 252.1 million at 30 June 2026, giving the company substantial capacity to fund clinical development and international expansion.

Clinuvel also declared a fully franked final Dividend of AUD 0.05 per share.

Outlook and Risks

Clinuvel remains financially supported by its established SCENESSE Franchise while investing in broader clinical programmes.

Its near-term growth outlook depends partly on expanding the commercial reach of its existing product and progressing additional indications.

The main risk is concentration around a relatively small number of programmes and the need for clinical development spending to translate into broader future revenue.

Mayne Pharma Group Limited (ASX:MYX)

Company Profile

Mayne Pharma operates across women’s health, dermatology and specialty pharmaceuticals.

Its portfolio includes established branded products across contraception, menopause and dermatology, supported by commercial operations in the United States and Australia.

FY2026 Financial Performance

Mayne Pharma reported FY2026 revenue of AUD 383.7 million.

Gross profit was AUD 248.1 million, representing a gross Margin of 64.7%.

Underlying EBITDA was AUD 34.2 million.

Women’s health revenue reached AUD 174.3 million, while dermatology generated AUD 138.7 million and the international Business contributed AUD 70.7 million.

Cash and marketable securities were approximately AUD 80 million at 30 June 2026.

Operating cash flow from continuing operations reached AUD 24.9 million.

Outlook and Risks

Mayne Pharma is focused on improving margins, expanding selected brands and strengthening distribution efficiency.

Its financial performance remains affected by product mix, returns and other operating costs.

Corporate uncertainty also remains following the termination of the proposed Takeover transaction and the continuation of associated legal and strategic-review processes.

Risks to Watch

Botanix faces the greatest near-term funding pressure because operating cash outflow remains high relative to available cash.

Clinuvel has the strongest Balance Sheet and profitability profile of the three, although future growth depends on successful execution beyond its established rare-disease franchise.

Mayne Pharma has the largest revenue base but continues to face pressure on underlying profitability and uncertainty around its corporate structure.

What Investors May Watch Through the Rest of 2026

For Botanix, prescription volumes, net revenue conversion and quarterly cash outflow may remain the key financial measures.

For Clinuvel, investors may focus on continued profitability, cash generation and progress across its development pipeline.

For Mayne Pharma, attention may remain on margin improvement, Operating Cash Flow and the outcome of its ongoing strategic and legal processes.

The three companies therefore represent different stages of specialty pharmaceutical development: Botanix is scaling a newer commercial product, Clinuvel is funding expansion from an established profitable franchise, and Mayne Pharma is working to improve earnings across a broader product portfolio.

FAQs

Q: What was Botanix Pharmaceuticals’ cash position at 30 June 2026?

A:Botanix reported cash of AUD 36.6 million at 30 June 2026, while FY2026 operating cash outflow was AUD 64.3 million.

Q: What did Clinuvel Pharmaceuticals report for FY2026?

A:Clinuvel reported revenue of AUD 94.0 million and net profit after tax of AUD 33.9 million. Cash reserves stood at AUD 252.1 million.

Q: What were Mayne Pharma’s key FY2026 figures?

A:Mayne Pharma reported revenue of AUD 383.7 million, underlying EBITDA of AUD 34.2 million and operating cash flow from continuing operations of AUD 24.9 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.